Rick Ewing
Vice President & Head of Chemistry Rapafusyn
Rick Ewing is Vice President and Head of Chemistry at Rapafusyn, a company focused on non-degrading molecular glues. Previously, he led drug discovery at the Barer Institute and spent many years at Bristol Myers Squibb, where he helped deliver 15 development candidates including Milvexian. He is a co-inventor on 79 patents, co-author of 77 publications, and recipient of multiple honors including ACS Fellow recognition.
Seminars
Thursday 28th January 2027
Chair’s Opening Remarks
8:50 am
Thursday 28th January 2027
Targeting Transcription Factors with Non-Degrading Molecular Glues to Expand Therapeutic Opportunities Beyond Oncology
10:00 am
- Harnessing non-degrading molecular glues to modulate transcription factor activity through induced proximity mechanisms, creating new opportunities to access historically challenging targets
- Demonstrating how STAT6-directed molecular glues can selectively reprogram immune signalling pathways, expanding the therapeutic potential of induced-proximity medicine beyond oncology applications
- Establishing a framework for the discovery and development of non-degrading molecular glues against immunological and transcriptional targets, broadening the future scope of the molecular glue modality
Thursday 28th January 2027
Panel Discussion: Deploying Molecular Glues to Tackle Neurodegeneration’s Toughest Targets
2:30 pm
- How can molecular glues be leveraged to target pathogenic protein aggregates and drive the selective clearance of disease-causing proteins across Alzheimer’s, Parkinson’s, and Huntington’s disease?
- What strategies are proving most effective for engineering brain-penetrant molecular glues that improve CNS exposure and target engagement while enhancing the translational potential of neurodegeneration programs?
- How can target engagement be most effectively validated in disease-relevant neuronal models to better understand therapeutic impact and de-risk progression into clinical development?
Thursday 28th January 2027
Chair’s Closing Remarks
4:30 pm
